Adial Pharmaceuticals, Inc.
ADIL
$3.25
-$0.18-5.11%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.24M | 1.15M | 1.52M | 1.21M | 1.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.76M | 1.88M | 2.27M | 1.94M | 2.21M |
| Operating Income | -1.76M | -1.88M | -2.27M | -1.94M | -2.21M |
| Income Before Tax | -1.79M | -1.96M | -2.23M | -2.07M | -2.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.79M | -1.96M | -2.23M | -2.07M | -2.19M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.79M | -1.96M | -2.23M | -2.07M | -2.19M |
| EBIT | -1.76M | -1.88M | -2.27M | -1.94M | -2.21M |
| EBITDA | -1.76M | -1.88M | -2.27M | -1.94M | -2.21M |
| EPS Basic | -2.02 | -4.61 | -8.52 | -8.07 | -9.39 |
| Normalized Basic EPS | -1.26 | -2.88 | -5.33 | -17.00 | -5.87 |
| EPS Diluted | -2.02 | -4.61 | -8.52 | -8.07 | -9.39 |
| Normalized Diluted EPS | -1.26 | -2.88 | -5.33 | -17.00 | -5.87 |
| Average Basic Shares Outstanding | 886.90K | 424.90K | 261.60K | 256.60K | 233.40K |
| Average Diluted Shares Outstanding | 886.90K | 424.90K | 261.60K | 256.60K | 233.40K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |